20 completed, 14 recruiting, 10 terminated, 8 unknown. 40 Phase 1, 22 Phase 2, 9 Phase 3, 2 Early Phase 1, 1 Not applicable.
Follow Relapsed or Refractory Multiple Myeloma: new trials by email Literature Review of Relapsed or Refractory Multiple Myeloma trials Research Report on Relapsed or Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | AbbVie | 520 | 2026-11-30 | 2026-07-27 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma AZD4045, Daratumumab, Aldesleukin - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 101 | 2026-07-27 | 2026-10-15 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 255 | 2026-06-11 | 2026-09-17 |
| A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma QLS32015, Pomalidomide, Selinexor - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 228 | 2025-11-07 | 2026-05-22 |
| Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D - Relapsed or Refractory Multiple Myeloma | Phase 1 | Recruiting | O&D BioTech Group CO., Limited | 18 | 2025-10-28 | 2026-01-27 |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma mRNA-2808 - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | ModernaTX, Inc. | 190 | 2025-09-30 | 2026-09-23 |
| Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma QLS32015, Pomalidomide, Dexamethasone - Relapsed or Refractory Multiple Myeloma | Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 160 | 2025-09-12 | 2026-06-08 |
| A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma F182112+P, F182112+CD38 - Relapsed or Refractory Multiple Myeloma | Phase 2 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 90 | 2025-07-02 | 2025-12-31 |
| Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy Zevorcabtagene Autoleucel - Relapsed or Refractory Multiple Myeloma | Not yet recruiting | CARsgen Therapeutics Co., Ltd. | 1500 | 2025-03-31 | 2025-02-13 | |
| A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma JNJ-87562761 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 17 | 2024-12-19 | 2026-09-25 |
| A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma QLS4131 Injection - Relapsed or Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 90 | 2024-08-30 | 2024-07-15 |
| A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Recruiting | Excyte Biopharma Ltd | 70 | 2024-06-14 | 2026-02-05 |
| Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma SIM0500 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 130 | 2024-05-24 | 2026-08-28 |
| To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma infusion of GPRC5D-CD19 CAR T injection - Relapsed or Refractory Multiple Myeloma | Early Phase 1 | Not yet recruiting | Guangdong Second Provincial General Hospital | 15 | 2024-03-29 | 2024-03-07 |
| A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. MBS314 Injection - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 154 | 2024-02-22 | 2024-03-15 |
| A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan Elotuzumab in combination with pomalidomide and dexamethasone, Elotuzumab in combination with lenalidomide and dexamethasone - Relapsed or Refractory Multiple Myeloma | Completed | Bristol-Myers Squibb | 7 | 2023-12-22 | 2025-07-31 | |
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma Forimtamig, Carfilzomib, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 21 | 2023-12-08 | 2026-09-29 |
| Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma BCMA/GPRC5D dual CAR-T - Relapsed or Refractory Multiple Myeloma | Not applicable | Terminated | Guangzhou Bio-gene Technology Co., Ltd | 1 | 2023-09-21 | 2026-03-17 |
| mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) mRNA-2736 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Withdrawn | ModernaTX, Inc. | 2023-08-15 | 2023-08-18 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) Cevostamab, Elranatamab, Tocilizumab - Relapsed or Refractory Multiple Myeloma | Phase 1 | Recruiting | Genentech, Inc. | 120 | 2023-08-10 | 2026-10-06 |
Showing 20 of 66. Sign in to see all of them.
Multiple Myeloma (66) · Recurrence (65) · Neoplasms (3) · Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms, Plasma Cell (2) · Amyloidosis (1) · Bone Marrow Neoplasms (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Neoplasm Metastasis (1)
Blood Protein Disorders (66) · Cardiovascular Diseases (66) · Hematologic Diseases (66) · Hemic and Lymphatic Diseases (66) · Hemorrhagic Disorders (66) · Hemostatic Disorders (66) · Immune System Diseases (66) · Immunoproliferative Disorders (66) · Lymphoproliferative Disorders (66) · Neoplasms by Histologic Type (66) · Paraproteinemias (66) · Vascular Diseases (66) · Disease Attributes (65) · Pathologic Processes (65) · Pathological Conditions, Signs and Symptoms (65)
Dexamethasone (19) · pomalidomide (12) · Bortezomib (8) · carfilzomib (7) · Lenalidomide (6) · daratumumab (6) · Calcium Dobesilate (5) · Cyclophosphamide (4) · Injections (4) · selinexor (3) · Azacitidine (2) · Vorinostat (2) · fludarabine (2) · talquetamab (2) · 130-nm albumin-bound paclitaxel (1)
Janssen Research & Development, LLC (6) · Amgen (5) · Qilu Pharmaceutical Co., Ltd. (4) · Altor BioScience (2) · Bristol-Myers Squibb (2) · Merck Sharp & Dohme LLC (2) · ModernaTX, Inc. (2) · Novartis Pharmaceuticals (2) · AbbVie (1) · Alliance Foundation Trials, LLC. (1) · Antengene Corporation (1) · AstraZeneca (1) · BeBetter Med Inc (1) · Beijing Mabworks Biotech Co., Ltd. (1) · CARsgen Therapeutics Co., Ltd. (1)
China (28) · United States (24) · Australia (13) · Germany (13) · Spain (13) · Canada (11) · France (8) · Japan (7) · United Kingdom (7) · Italy (6) · Netherlands (6) · Greece (5) · South Korea (5) · Austria (4) · Israel (4)
Lugui Qiu (2) · Amitabha Mazumder, MD (1) · Axel Glasmacher, MD (1) · Depei Wu (1) · Edward Stadtmauer, MD (1) · Gang An (1) · Gang An, MD, Ph.D (1) · Hing C Wong, PhD (1)
PMID 36100310, PMID 24562384, PMID 25402977, PMID 25809731, PMID 27025160, PMID 36608320, PMID 37192741, PMID 38794892, PMID 39024542, PMID 40000533, PMID 40232151, PMID 40547010, PMID 40826257, PMID 41100731, PMID 42212933, PMID 42287565, PMID 42289183
2023 (6), 2018 (2), 2008 (1), 2009 (1), 2014 (1), 2015 (1), 2017 (1), 2019 (1)